ALMR
Alamar Biosciences, Inc.
NasdaqGS Healthcare United States
28,16 $US
+7.07% today
+28.00% YTD · +28.00% 1Y
14
Insider transactions
SEC Form 4 · AMF · BaFin — rolling 90 days
15
Hedge funds tracked
Latest available SEC 13F filings
64
/ 100
STRONG

Analysis Alamar Biosciences, Inc. (ALMR) — Kairos Score 64/100

Composite score aggregating 8 smart money dimensions: insiders (SEC/AMF/BaFin), hedge funds, politicians & gurus, price momentum, valuation, analyst consensus, financial health, earnings momentum. The higher the score, the more favorable the institutional signals consensus.

💡 Detailed breakdown (the 8 sub-scores) available in the Premium dashboard.

About Alamar Biosciences, Inc.

Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnostics. The company's offering is utilized in research areas including immunology, neurology, and oncology. It serves global research and academic institutions, biopharmaceutical companies, contract research organizations, and service labs. The company operates in the United States, rest of Europe, Middle East and Africa, Germany, Asia Pacific, and internationally. It has a strategic partnership with Alzheimer's Disease Data Initiative, and Gates Ventures to advance translational research in alzheimer's disease. The company was incorporated in 2018 and is based in Fremont, California.

Key info

👔
CEO
Dr. Yuling Luo Ph.D.
📍
HQ
47071 Bayside Parkway, Fremont, CA, 94538, United States
👥
Employees
286
💰
Market cap
1 954 100 352,00 $US
💸
Dividend yield
0.00%

🕴️ Insider activity (90 days)

14 transactions — 0 buys and 12 sales reported by Alamar Biosciences, Inc. executives.

QC
Qiming Corporate GP VI, Ltd.
2026-10-16
Sell
QC
Qiming Corporate GP VI, Ltd.
2026-10-16
Sell
QC
Qiming Corporate GP VI, Ltd.
2026-10-16
Sell

🏦 Hedge Funds

15 institutional funds report a position on ALMR in their latest SEC quarterly filing.

ARK Investment Management LLC
ALLIANCEBERNSTEIN L.P.
BlackRock, Inc.
MILLENNIUM MANAGEMENT LLC
FMR LLC

📰 Recent news

15 recent articles on ALMR.

🧠 What makes Kairos Insider

Beyond raw data, we aggregate and score every smart money signal to give you a unique view.

🧠

Kairos Score 0-100

8-dimension composite score: insiders · hedge funds · politicians · momentum · valuation · health · analysts · earnings.

🎯

Insider Clusters

Detection of clustered purchases or sales by several executives in the same stock.

🏦

13F Hedge Funds

Berkshire, Pershing Square, Tiger Global, Bridgewater and other reporting funds.

📈

ETF Rotations

NANC & GOP (Pelosi & Republicans), GURU (top hedge funds), ARK (Cathie Wood). See who enters and exits each week.

🔥

Google Trends

Spot marked changes in search interest around the stocks being followed.

📧

Email alerts

Create your watchlist and receive a brief of events affecting your tickers.

Companies in the same sector as Alamar Biosciences, Inc.

Official sources · Public data · SEC EDGAR — Form 4 & 13F · AMF — Executive filings · BaFin — Directors' Dealings · Yahoo Finance · Alpha Vantage

🔓 Unlock the full analysis

This public page only shows a preview. The full analysis of ALMR on the Kairos Insider dashboard includes:

✅ Full Kairos Score (8-axis radar + synthesis)
✅ History of all 14 insider transactions over 90 days
✅ All 15 detected institutional funds
✅ Thematic ETFs (ARK, BUZZ, NANC, GOP, JEPI…)
✅ Hot Stocks Google Trends
✅ Available history: AUM + rotations
✅ Fundamentals (P/E, PEG, EV/EBITDA, ROE…)
✅ Financial health (Altman Z, Piotroski F)
✅ Sector peers + recent earnings
See full analysis →
Analyze other tickers for free →

Free signup · Pro €19/month or €190/year